NWIPB OpenIR
Luteolin inhibits ROS-activated MAPK pathway in myocardial ischemia/reperfusion injury
Yu, Dongsheng1,2; Li, Mengwen1,2; Tian, Youqing3; Liu, Jun1,2; Shang, Jing1,2,4; Shang, J (reprint author), China Pharmaceut Univ, Ctr Drug Screening, 24 Tong Jia Xiang, Nanjing 210009, Jiangsu, Peoples R China.
2015-02-01
Source PublicationLIFE SCIENCES
Volume122Pages:15-25
SubtypeArticle
AbstractAims: Luteolin is a falconoid compound that has an antioxidant effect, but its contribution to ROS-activated MAPK pathways in ischemia/reperfusion injury is seldom reported. Here, we have confirmed that it exhibits an antioxidant effect in myocardial ischemia/reperfusion injury (MIRI) by inhibiting ROS-activated MAPK pathways. Main methods: We exposed rat hearts into the left anterior descending coronary artery (LAD) ligation for 30 min followed by 1 h of reperfusion. Observations were carried out using electrocardiography; detection of hemodynamic parameters; and testing levels of lactate dehydrogenase (LDH), creatine kinase (CK), total superoxide dismutase (T-SOD), and malondialdehyde (MDA). Mitogen-activated protein kinase (MAPK) pathway was measured by western blot and transmission electron microscopy was applied to observe the myocardial ultrastructure. Rat H9c2 cell in 95% N-2 and 5% CO2 stimulated the MIRI. Oxidation system mRNA levels were measured by real-time PCR; mitochondrial membrane potential and apoptosis were measured by confocal microscopy and flow cytometry; western blot analysis was used to assay caspase-3, -8, and -9 and MAPK pathway protein expression; the MAPK pathway was inhibited using SB203580 (p38 MAPK inhibitor) and SP600125 (c-Jun NH2-terminal kinase inhibitor) before H9c2 cells were exposed to hypoxia/reoxygenation injury to show the modulation of the changes in ROS generation, cell viability and apoptosis. Key findings: In vivo, luteolin can ameliorate the impaired mitochondrial morphology, regulating the MAPK pathway to protect MIRI. In vitro, luteolin can affect the oxidation system, mitochondrial membrane potential and MAPK pathway to anti-apoptosis. Significance: These results reveal a ROS-MAPK mediated mechanism and mitochondrial pathway through which luteolin can protect myocardial ischemia/reperfusion injury. (C) 2014 Elsevier Inc. All rights reserved.; Aims: Luteolin is a falconoid compound that has an antioxidant effect, but its contribution to ROS-activated MAPK pathways in ischemia/reperfusion injury is seldom reported. Here, we have confirmed that it exhibits an antioxidant effect in myocardial ischemia/reperfusion injury (MIRI) by inhibiting ROS-activated MAPK pathways.
KeywordLuteolin Myocardial Ischemia/reperfusion Injury Reactive Oxygen Species Mapk Mitochondrial Apoptosis
WOS HeadingsScience & Technology ; Life Sciences & Biomedicine
WOS KeywordISCHEMIA-REPERFUSION INJURY ; UP-REGULATION ; INFARCT SIZE ; IN-VITRO ; APOPTOSIS ; CELLS ; PROTECTS ; HYPOXIA/REOXYGENATION ; KINASE ; HEART
Indexed BySCI
Language英语
WOS Research AreaResearch & Experimental Medicine ; Pharmacology & Pharmacy
WOS SubjectMedicine, Research & Experimental ; Pharmacology & Pharmacy
WOS IDWOS:000349508500003
Citation statistics
Cited Times:56[WOS]   [WOS Record]     [Related Records in WOS]
Document Type期刊论文
Identifierhttp://210.75.249.4/handle/363003/5458
Collection中国科学院西北高原生物研究所
Corresponding AuthorShang, J (reprint author), China Pharmaceut Univ, Ctr Drug Screening, 24 Tong Jia Xiang, Nanjing 210009, Jiangsu, Peoples R China.
Affiliation1.China Pharmaceut Univ, Ctr Drug Screening, Nanjing 210009, Jiangsu, Peoples R China
2.China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Jiangsu, Peoples R China
3.Jiangsu Union Tech Inst, Lianyungang TCM Branch, Lianyungang 222007, Peoples R China
4.Chinese Acad Sci, Northwest Inst Plateau Biol, Qinghai Key Lab Tibetan Med Pharmacol & Safety Ev, Xining 810008, Peoples R China
Recommended Citation
GB/T 7714
Yu, Dongsheng,Li, Mengwen,Tian, Youqing,et al. Luteolin inhibits ROS-activated MAPK pathway in myocardial ischemia/reperfusion injury[J]. LIFE SCIENCES,2015,122:15-25.
APA Yu, Dongsheng,Li, Mengwen,Tian, Youqing,Liu, Jun,Shang, Jing,&Shang, J .(2015).Luteolin inhibits ROS-activated MAPK pathway in myocardial ischemia/reperfusion injury.LIFE SCIENCES,122,15-25.
MLA Yu, Dongsheng,et al."Luteolin inhibits ROS-activated MAPK pathway in myocardial ischemia/reperfusion injury".LIFE SCIENCES 122(2015):15-25.
Files in This Item: Download All
File Name/Size DocType Version Access License
Yu-2015-Luteolin inh(1649KB) 开放获取CC BY-NC-SAView Download
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Yu, Dongsheng]'s Articles
[Li, Mengwen]'s Articles
[Tian, Youqing]'s Articles
Baidu academic
Similar articles in Baidu academic
[Yu, Dongsheng]'s Articles
[Li, Mengwen]'s Articles
[Tian, Youqing]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Yu, Dongsheng]'s Articles
[Li, Mengwen]'s Articles
[Tian, Youqing]'s Articles
Terms of Use
No data!
Social Bookmark/Share
File name: Yu-2015-Luteolin inhibits RO.pdf
Format: Adobe PDF
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.